nach oben

Current Hypertension Reports

Erschienen in:

01.03.2016 | Hypertension and Obesity (E Reisin, Section Editor)

Aldosterone Production and Signaling Dysregulation in Obesity

verfasst von: Andrea Vecchiola, Carlos F. Lagos, Cristian A. Carvajal, Rene Baudrand, Carlos E. Fardella

Erschienen in: Current Hypertension Reports | Ausgabe 3/2016

Einloggen, um Zugang zu erhalten

Abstract

In the past decades, we have extended the view of aldosterone effects beyond epithelial tissues. New evidence regarding the aldosterone/mineralocorticoid receptor (MR) pathway in active metabolic tissues, including adipose tissue, has confirmed its pathogenic role in systemic inflammation, endothelial dysfunction, insulin resistance, and dyslipidemia. Obesity, a current epidemic worldwide, increases aldosterone production by several adipocyte factors such as leptin but is also associated with local aldosterone production. In addition, obesity can modulate MR activation leading to signaling dysregulation and a pro-inflammatory profile of adipocytes. Current knowledge have deciphered that this phenotypical differences of obesity may be explained, at least in part, by novel non-genomic activation of MR, new inducers of aldosterone synthesis, and probably by several epigenetic modifications. In addition, with the understanding of the complex interplay of obesity, hormones, and receptors, targeted pharmacological therapy is expected and is currently under active research.

Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104(4):545–56.PubMedCrossRef

Spat A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev. 2004;84(2):489–539. doi:10.1152/physrev.00030.2003.PubMedCrossRef

Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Physiol. 2014;4(3):965–94. doi:10.1002/cphy.c130044.PubMedPubMedCentralCrossRef

Muller-Fielitz H, Lau M, Johren O, Stellmacher F, Schwaninger M, Raasch W. Blood pressure response to angiotensin II is enhanced in obese Zucker rats and is attributed to an aldosterone-dependent mechanism. Br J Pharmacol. 2012;166(8):2417–29. doi:10.1111/j.1476-5381.2012.01953.x.PubMedPubMedCentralCrossRef

Tomaschitz A, Pilz S, Ritz E, Obermayer-Pietsch B, Pieber TR. Aldosterone and arterial hypertension. Nat Rev Endocrinol. 2010;6(2):83–93. doi:10.1038/nrendo.2009.263.PubMedCrossRef

Marver D, Kokko JP. Renal target sites and the mechanism of action of aldosterone. Miner Electrolyte Metab. 1983;9(1):1–18.PubMed

Jaffe IZ, Mendelsohn ME. Angiotensin II and aldosterone regulate gene transcription via functional mineralocorticoid receptors in human coronary artery smooth muscle cells. Circ Res. 2005;96(6):643–50. doi:10.1161/01.RES.0000159937.05502.d1.PubMedCrossRef

NRN Committee. A unified nomenclature system for the nuclear receptor superfamily. Cell. 1999;97:161–3.CrossRef

Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension. 2005;46(6):1227–35. doi:10.1161/01.HYP.0000193502.77417.17.PubMedCrossRef

10.

Naray-Fejes-Toth A, Fejes-Toth G. The sgk, an aldosterone-induced gene in mineralocorticoid target cells, regulates the epithelial sodium channel. Kidney Int. 2000;57(4):1290–4. doi:10.1046/j.1523-1755.2000.00964.x.PubMedCrossRef

11.

Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation. 1995;92(2):175–82.PubMedCrossRef

12.

Takeda Y, Miyamori I, Inaba S, Furukawa K, Hatakeyama H, Yoneda T, et al. Vascular aldosterone in genetically hypertensive rats. Hypertension. 1997;29(1 Pt 1):45–8.PubMedCrossRef

13.

Zhou MY, Gomez-Sanchez CE, Gomez-Sanchez EP. An alternatively spliced rat mineralocorticoid receptor mRNA causing truncation of the steroid binding domain. Mol Cell Endocrinol. 2000;159(1–2):125–31.PubMedCrossRef

14.

Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009;54(3):537–43. doi:10.1161/HYPERTENSIONAHA.109.131110.PubMedCrossRef

15.

Rickard AJ, Young MJ. Corticosteroid receptors, macrophages and cardiovascular disease. J Mol Endocrinol. 2009;42(6):449–59. doi:10.1677/JME-08-0144.PubMedCrossRef

16.

Carvajal CA, Herrada AA, Castillo CR, Contreras FJ, Stehr CB, Mosso LM, et al. Primary aldosteronism can alter peripheral levels of transforming growth factor beta and tumor necrosis factor alpha. J Endocrinol Investig. 2009;32(9):759–65. doi:10.3275/6429.CrossRef

17.

Herrada AA, Contreras FJ, Marini NP, Amador CA, Gonzalez PA, Cortes CM, et al. Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity. J Immunol. 2010;184(1):191–202. doi:10.4049/jimmunol.0802886.PubMedCrossRef

18.

Calhoun DA, Sharma K. The role of aldosteronism in causing obesity-related cardiovascular risk. Cardiol Clin. 2010;28(3):517–27. doi:10.1016/j.ccl.2010.04.001.PubMedPubMedCentralCrossRef

19.

Pimenta E, Calhoun DA. Aldosterone and metabolic dysfunction: an unresolved issue. Hypertension. 2009;53(4):585–6. doi:10.1161/HYPERTENSIONAHA.108.123406.PubMedCrossRef

20.

Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150(11):776–83.PubMedPubMedCentralCrossRef

21.

Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocr Rev. 2008;29(7):777–822. doi:10.1210/er.2008-0024.PubMedCrossRef

22.•

Vaidya A, Underwood PC, Hopkins PN, Jeunemaitre X, Ferri C, Williams GH, et al. Abnormal aldosterone physiology and cardiometabolic risk factors. Hypertension. 2013;61(4):886–93. doi:10.1161/HYPERTENSIONAHA.111.00662. This report presents new information, whether novel indices of aldosterone responses to dietary sodium modulation, could predict cardiometabolic risk factors. The integration of aldosterone suppression and stimulation would provide an improved representation of aldosterone physiology in disease states that could offer new insights in the pathogenesis and treatment of cardiometabolic derangements.PubMedPubMedCentralCrossRef

23.

Harada E, Mizuno Y, Katoh D, Kashiwagi Y, Morita S, Nakayama Y, et al. Increased urinary aldosterone excretion is associated with subcutaneous not visceral, adipose tissue area in obese individuals: a possible manifestation of dysfunctional subcutaneous adipose tissue. Clin Endocrinol. 2013;79(4):510–6. doi:10.1111/cen.12083.CrossRef

24.

Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91(2):454–9. doi:10.1210/jc.2005-1733.PubMedCrossRef

25.

Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation. 2007;116(9):984–92. doi:10.1161/CIRCULATIONAHA.107.708537.PubMedCrossRef

26.

Rowe JW, Tobin JD, Rosa RM, Andres R. Effect of experimental potassium deficiency on glucose and insulin metabolism. Metab Clin Exp. 1980;29(6):498–502.PubMedCrossRef

27.

Ferrannini E, Galvan AQ, Santoro D, Natali A. Potassium as a link between insulin and the renin-angiotensin-aldosterone system. J Hypertens Suppl. 1992;10(1):S5–10.PubMedCrossRef

28.

Luther JM. Effects of aldosterone on insulin sensitivity and secretion. Steroids. 2014;91:54–60. doi:10.1016/j.steroids.2014.08.016.PubMedCrossRef

29.

Luther JM, Brown NJ. The renin-angiotensin-aldosterone system and glucose homeostasis. Trends Pharmacol Sci. 2011;32(12):734–9. doi:10.1016/j.tips.2011.07.006.PubMedPubMedCentralCrossRef

30.

Luther JM, Luo P, Kreger MT, Brissova M, Dai C, Whitfield TT, et al. Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia. 2011;54(8):2152–63. doi:10.1007/s00125-011-2158-9.PubMedPubMedCentralCrossRef

31.

Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, et al. A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens. 2007;25(10):2125–30. doi:10.1097/HJH.0b013e3282861fa4.PubMedCrossRef

32.

Garg R, Hurwitz S, Williams GH, Hopkins PN, Adler GK. Aldosterone production and insulin resistance in healthy adults. J Clin Endocrinol Metab. 2010;95(4):1986–90. doi:10.1210/jc.2009-2521.PubMedPubMedCentralCrossRef

33.

Williams TA, Monticone S, Urbanet R, Bertello C, Giraudo G, Vettor R, et al. Genes implicated in insulin resistance are down-regulated in primary aldosteronism patients. Mol Cell Endocrinol. 2012;355(1):162–8. doi:10.1016/j.mce.2012.02.007.PubMedCrossRef

34.

Rossi GP, Belfiore A, Bernini G, Fabris B, Caridi G, Ferri C, et al. Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab. 2008;93(7):2566–71. doi:10.1210/jc.2008-0251.PubMedCrossRef

35.

Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45(3):356–62. doi:10.1161/01.HYP.0000154361.47683.d3.PubMedCrossRef

36.•

Briones AM, Nguyen Dinh Cat A, Callera GE, Yogi A, Burger D, He Y, et al. Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension. 2012;59(5):1069–78. doi:10.1161/HYPERTENSIONAHA.111.190223. Adipocytes possess aldosterone synthase and produce aldosterone in an Ang II/Ang II type 1 receptor/calcineurin/nuclear factor of activated T-cells–dependent manner. identifying adipocytes as a putative link between aldosterone and vascular dysfunction in diabetes mellitus–associated obesity.PubMedCrossRef

37.

Schinner S, Willenberg HS, Krause D, Schott M, Lamounier-Zepter V, Krug AW, et al. Adipocyte-derived products induce the transcription of the StAR promoter and stimulate aldosterone and cortisol secretion from adrenocortical cells through the Wnt-signaling pathway. Int J Obes. 2007;31(5):864–70. doi:10.1038/sj.ijo.0803508.

38.

Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17(12):3438–46. doi:10.1681/ASN.2006080944.PubMedCrossRef

39.

Lamounier-Zepter V, Ehrhart-Bornstein M, Bornstein SR. Mineralocorticoid-stimulating activity of adipose tissue. Best Pract Res Clin Endocrinol Metab. 2005;19(4):567–75. doi:10.1016/j.beem.2005.07.002.PubMedCrossRef

40.

Ehrhart-Bornstein M, Arakelyan K, Krug AW, Scherbaum WA, Bornstein SR. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res. 2004;30(4):865–70.PubMedCrossRef

41.

Goodfriend TL, Ball DL, Raff H, Bruder ED, Gardner HW, Spiteller G. Oxidized products of linoleic acid stimulate adrenal steroidogenesis. Endocr Res. 2002;28(4):325–30.PubMedCrossRef

42.

de Haro MC, Figueiredo VN, de Faria AP, Barbaro NR, Sabbatini AR, Quinaglia T, et al. High-circulating leptin levels are associated with increased blood pressure in uncontrolled resistant hypertension. J Hum Hypertens. 2013;27(4):225–30. doi:10.1038/jhh.2012.29.CrossRef

43.•

Huby AC, Antonova G, Groenendyk J, Gomez-Sanchez CE, Bollag WB, Filosa JA, et al. The adipocyte-derived hormone leptin is a direct regulator of aldosterone secretion, which promotes endothelial dysfunction and cardiac fibrosis. Circulation. 2015. doi:10.1161/CIRCULATIONAHA.115.018226. This report presents key information on the adipokine leptin is a direct regulator of aldosterone synthase (CYP11B2) expression and aldosterone release and promotes cardiovascular dysfunction via aldosterone-dependent mechanisms.PubMed

44.

Luo P, Dematteo A, Wang Z, Zhu L, Wang A, Kim HS, et al. Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice. Diabetologia. 2013;56(4):901–10. doi:10.1007/s00125-012-2814-8.PubMedPubMedCentralCrossRef

45.

Baudrand R, Pojoga LH, Romero JR, Williams GH. Aldosterone’s mechanism of action: roles of lysine-specific demethylase 1, caveolin and striatin. Curr Opin Nephrol Hypertens. 2014;23(1):32–7. doi:10.1097/01.mnh.0000436543.48391.e0.PubMedCrossRef

46.

Shibata S, Fujita T. The kidneys and aldosterone/mineralocorticoid receptor system in salt-sensitive hypertension. Curr Hypertens Rep. 2011;13(2):109–15. doi:10.1007/s11906-010-0175-6.PubMedPubMedCentralCrossRef

47.

Zennaro MC, Le Menuet D, Viengchareun S, Walker F, Ricquier D, Lombes M. Hibernoma development in transgenic mice identifies brown adipose tissue as a novel target of aldosterone action. J Clin Invest. 1998;101(6):1254–60. doi:10.1172/JCI1915.PubMedPubMedCentralCrossRef

48.

Viengchareun S, Penfornis P, Zennaro MC, Lombes M. Mineralocorticoid and glucocorticoid receptors inhibit UCP expression and function in brown adipocytes. Am J Physiol Endocrinol Metab. 2001;280(4):E640–9.PubMed

49.

Penfornis P, Viengchareun S, Le Menuet D, Cluzeaud F, Zennaro MC, Lombes M. The mineralocorticoid receptor mediates aldosterone-induced differentiation of T37i cells into brown adipocytes. Am J Physiol Endocrinol Metab. 2000;279(2):E386–94.PubMed

50.

Caprio M, Feve B, Claes A, Viengchareun S, Lombes M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 2007;21(9):2185–94. doi:10.1096/fj.06-7970com.PubMedCrossRef

51.

Skurk T, Alberti-Huber C, Herder C, Hauner H. Relationship between adipocyte size and adipokine expression and secretion. J Clin Endocrinol Metab. 2007;92(3):1023–33. doi:10.1210/jc.2006-1055.PubMedCrossRef

52.

Bluher M. Are there still healthy obese patients? Curr Opin Endocrinol Diabetes Obes. 2012;19(5):341–6. doi:10.1097/MED.0b013e328357f0a3.PubMedCrossRef

53.

Kloting N, Fasshauer M, Dietrich A, Kovacs P, Schon MR, Kern M, et al. Insulin-sensitive obesity. Am J Physiol Endocrinol Metab. 2010;299(3):E506–15. doi:10.1152/ajpendo.00586.2009.PubMedCrossRef

54.

Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008;117(17):2253–61. doi:10.1161/CIRCULATIONAHA.107.748640.PubMedPubMedCentralCrossRef

55.

Hirata A, Maeda N, Nakatsuji H, Hiuge-Shimizu A, Okada T, Funahashi T, et al. Contribution of glucocorticoid-mineralocorticoid receptor pathway on the obesity-related adipocyte dysfunction. Biochem Biophys Res Commun. 2012;419(2):182–7. doi:10.1016/j.bbrc.2012.01.139.PubMedCrossRef

56.

Boscaro M, Giacchetti G, Ronconi V. Visceral adipose tissue: emerging role of gluco- and mineralocorticoid hormones in the setting of cardiometabolic alterations. Ann N Y Acad Sci. 2012;1264:87–102. doi:10.1111/j.1749-6632.2012.06597.x.PubMedPubMedCentralCrossRef

57.•

Armani A, Marzolla V, Fabbri A, Caprio M. Cellular mechanisms of MR regulation of adipose tissue physiology and pathophysiology. J Mol Endocrinol. 2015;55(2):R1–10. doi:10.1530/JME-15-0122. This review summarizes the functions of cellular mechanisms of MR in the adipocyte, discusses potential signaling pathways mediating MR action, and describes post-translational modifications regulating its activity.PubMedCrossRef

58.

Berger S, Bleich M, Schmid W, Greger R, Schutz G. Mineralocorticoid receptor knockout mice: lessons on Na + metabolism. Kidney Int. 2000;57(4):1295–8. doi:10.1046/j.1523-1755.2000.00965.x.PubMedCrossRef

59.

Bleich M, Warth R, Schmidt-Hieber M, Schulz-Baldes A, Hasselblatt P, Fisch D, et al. Rescue of the mineralocorticoid receptor knock-out mouse. Pflugers Arch - Eur J Physiol. 1999;438(3):245–54. doi:10.1007/s004240050906.CrossRef

60.

Lim HY, van den Brandt J, Fassnacht M, Allolio B, Herold MJ, Reichardt HM. Silencing of the mineralocorticoid receptor by ribonucleic acid interference in transgenic rats disrupts endocrine homeostasis. Mol Endocrinol. 2008;22(6):1304–11. doi:10.1210/me.2007-0417.PubMedCrossRef

61.

Ronzaud C, Loffing J, Bleich M, Gretz N, Grone HJ, Schutz G, et al. Impairment of sodium balance in mice deficient in renal principal cell mineralocorticoid receptor. J Am Soc Nephrol. 2007;18(6):1679–87. doi:10.1681/ASN.2006090975.PubMedCrossRef

62.

Ronzaud C, Loffing J, Gretz N, Schutz G, Berger S. Inducible renal principal cell-specific mineralocorticoid receptor gene inactivation in mice. Am J Physiol Renal Physiol. 2011;300(3):F756–60. doi:10.1152/ajprenal.00728.2009.PubMedCrossRef

63.

Grossmann C, Benesic A, Krug AW, Freudinger R, Mildenberger S, Gassner B, et al. Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol. 2005;19(7):1697–710. doi:10.1210/me.2004-0469.PubMedCrossRef

64.

Dooley R, Harvey BJ, Thomas W. Non-genomic actions of aldosterone: from receptors and signals to membrane targets. Mol Cell Endocrinol. 2012;350(2):223–34. doi:10.1016/j.mce.2011.07.019.PubMedCrossRef

65.

Munoz-Durango N, Barake MF, Letelier NA, Campino C, Fardella CE, Kalergis AM. Immune system alterations by aldosterone during hypertension: from clinical observations to genomic and non-genomic mechanisms leading to vascular damage. Curr Mol Med. 2013;13(6):1035–46.PubMedCrossRef

66.

Yogi A, Callera GE, O'Connor S, Antunes TT, Valinsky W, Miquel P, et al. Aldosterone signaling through transient receptor potential melastatin 7 cation channel (TRPM7) and its alpha-kinase domain. Cell Signal. 2013;25(11):2163–75. doi:10.1016/j.cellsig.2013.07.002.PubMedPubMedCentralCrossRef

67.

Gros R, Ding Q, Sklar LA, Prossnitz EE, Arterburn JB, Chorazyczewski J, et al. GPR30 expression is required for the mineralocorticoid receptor–independent rapid vascular effects of aldosterone. Hypertension. 2011;57(3):442–51. doi:10.1161/hypertensionaha.110.161653.PubMedCrossRef

68.

Caroccia B, Seccia TM, Campos AG, Gioco F, Kuppusamy M, Ceolotto G, et al. GPER-1 and estrogen receptor-beta ligands modulate aldosterone synthesis. Endocrinology. 2014;155(11):4296–304. doi:10.1210/en.2014-1416.PubMedCrossRef

69.

Sharma G, Hu C, Brigman JL, Zhu G, Hathaway HJ, Prossnitz ER. GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state. Endocrinology. 2013;154(11):4136–45. doi:10.1210/en.2013-1357.PubMedPubMedCentralCrossRef

70.

Zhu P, Yuen JML, Sham KWY, Cheng CHK. GPER mediates the inhibitory actions of estrogen on adipogenesis in 3T3-L1 cells through perturbation of mitotic clonal expansion. Gen Comp Endocrinol. 2013;193:19–26. doi:10.1016/j.ygcen.2013.07.004.PubMedCrossRef

71.

Friso S, Carvajal CA, Fardella CE, Olivieri O. Epigenetics and arterial hypertension: the challenge of emerging evidence. Transl Res. 2015;165(1):154–65. doi:10.1016/j.trsl.2014.06.007.PubMedCrossRef

72.

Choi SW, Friso S. Epigenetics: a new bridge between nutrition and health. Adv Nutr. 2010;1(1):8–16. doi:10.3945/an.110.1004.PubMedPubMedCentralCrossRef

73.•

Demura M, Demura Y, Takeda Y, Saijoh K. Dynamic regulation of the angiotensinogen gene by DNA methylation, which is influenced by various stimuli experienced in daily life. Hypertens Res. 2015;38(8):519–27. doi:10.1038/hr.2015.42. This review highlights new evidences of epigenetic control of angiotensin gene (Agt) in adipose tissue. Agt gene, a RAAS gene, dynamically change its expression because exogenous and endogenous factors, as salt, glucocorticoids and mineralocorticoids in visceral adipose tissue.PubMedCrossRef

74.

Wang F, Demura M, Cheng Y, Zhu A, Karashima S, Yoneda T, et al. Dynamic CCAAT/enhancer binding protein-associated changes of DNA methylation in the angiotensinogen gene. Hypertension. 2014;63(2):281–8. doi:10.1161/HYPERTENSIONAHA.113.02303.PubMedCrossRef

75.

Howard B, Wang Y, Xekouki P, Faucz FR, Jain M, Zhang L, et al. Integrated analysis of genome-wide methylation and gene expression shows epigenetic regulation of CYP11B2 in aldosteronomas. J Clin Endocrinol Metab. 2014;99(3):E536–43. doi:10.1210/jc.2013-3495.PubMedPubMedCentral

76.

Robertson S, MacKenzie SM, Alvarez-Madrazo S, Diver LA, Lin J, Stewart PM, et al. MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex. Hypertension. 2013;62(3):572–8. doi:10.1161/HYPERTENSIONAHA.113.01102.PubMedCrossRef

77.

Sober S, Laan M, Annilo T. MicroRNAs miR-124 and miR-135a are potential regulators of the mineralocorticoid receptor gene (NR3C2) expression. Biochem Biophys Res Commun. 2010;391(1):727–32. doi:10.1016/j.bbrc.2009.11.128.PubMedPubMedCentralCrossRef

78.

Kemp JR, Unal H, Desnoyer R, Yue H, Bhatnagar A, Karnik SS. Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin-angiotensin system. J Mol Cell Cardiol. 2014;75:25–39. doi:10.1016/j.yjmcc.2014.06.008.PubMedPubMedCentralCrossRef

79.

Misra M. Obesity pharmacotherapy: current perspectives and future directions. Curr Cardiol Rev. 2013;9(1):33–54.PubMedPubMedCentral

80.

Khorassani FE, Misher A, Garris S. Past and present of antiobesity agents: focus on monoamine modulators. Am J Health Syst Pharm. 2015;72(9):697–706. doi:10.2146/ajhp140034.PubMedCrossRef

81.

Costantino L, Barlocco D. New perspectives on the development of antiobesity drugs. Future Med Chem. 2015;7(3):315–36. doi:10.4155/fmc.14.167.PubMedCrossRef

82.

Gomez-Sanchez CE. What is the role of the adipocyte mineralocorticoid receptor in the metabolic syndrome? Hypertension. 2015;66(1):17–9. doi:10.1161/HYPERTENSIONAHA.115.05148.PubMedCrossRef

83.

Jing F, Mogi M, Horiuchi M. Role of renin–angiotensin–aldosterone system in adipose tissue dysfunction. Mol Cell Endocrinol. 2013;378(1–2):23–8. doi:10.1016/j.mce.2012.03.005.PubMedCrossRef

84.

Brown NJ. This is not Dr. Conn’s aldosterone anymore. Trans Am Clin Climatol Assoc. 2011;122:229–43.PubMedPubMedCentral

85.

Fontana V, de Faria AP, Oliveira-Paula GH, Silva PS, Biagi C, Tanus-Santos JE, et al. Effects of angiotensin-converting enzyme inhibition on leptin and adiponectin levels in essential hypertension. Basic Clin Pharmacol Toxicol. 2014;114(6):472–5. doi:10.1111/bcpt.12195.PubMedCrossRef

86.

Nedogoda SV, Ledyaeva AA, Chumachok EV, Tsoma VV, Mazina G, Salasyuk AS, et al. Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. Clin Drug Investig. 2013;33(8):553–61. doi:10.1007/s40261-013-0094-9.PubMedCrossRef

87.

Sarzani R, Guerra F, Mancinelli L, Buglioni A, Franchi E, Dessi-Fulgheri P. Plasma aldosterone is increased in class 2 and 3 obese essential hypertensive patients despite drug treatment. Am J Hypertens. 2012;25(7):818–26. doi:10.1038/ajh.2012.47.PubMedCrossRef

88.

Schrier RW. Aldosterone ‘escape’ vs ‘breakthrough’. Nat Rev Nephrol. 2010;6(2):61. doi:10.1038/nrneph.2009.228.PubMedCrossRef

89.

Marcus Y, Shefer G, Sasson K, Kohen F, Limor R, Pappo O, et al. Angiotensin 1–7 as means to prevent the metabolic syndrome: lessons from the fructose-fed rat model. Diabetes. 2013;62(4):1121–30. doi:10.2337/db12-0792.PubMedPubMedCentralCrossRef

90.

Schuchard J, Winkler M, Stölting I, Schuster F, Vogt FM, Barkhausen J, et al. Lack of weight gain after angiotensin AT1 receptor blockade in diet-induced obesity is partly mediated by an angiotensin-(1–7)/Mas-dependent pathway. Br J Pharmacol. 2015;172(15):3764–78. doi:10.1111/bph.13172.PubMedCrossRef

91.•

Azizi M, Amar L, Menard J. Aldosterone synthase inhibition in humans. Nephrol Dial Transplant. 2013;28(1):36–43. doi:10.1093/ndt/gfs388. This review summarizes recent in vitro and preclinical studies of CYP11B2 inhibitors, hormonal and haemodynamic effects, and highlights potential side-effects as a class.PubMedCrossRef

92.

Papillon JPN, Lou C, Singh AK, Adams CM, Ksander GM, Beil ME, et al. Discovery of N-[5-(6-chloro-3-cyano-1-methyl-1H-indol-2-yl)-pyridin-3-ylmethyl]-ethanesulfonamide, a cortisol-sparing CYP11B2 inhibitor that lowers aldosterone in human subjects. J Med Chem. 2015. doi:10.1021/acs.jmedchem.5b01545.

93.•

Strushkevich N, Gilep AA, Shen L, Arrowsmith CH, Edwards AM, Usanov SA, et al. Structural insights into aldosterone synthase substrate specificity and targeted inhibition. Mol Endocrinol. 2013;27(2):315–24. doi:10.1210/me.2012-1287. This paper reports the crystal structures of human aldosterone synthase in complex with a substrate deoxycorticosterone and an first generation CYP11B2 inhibitor fadrozole.PubMedCrossRef

94.

Cerny MA, Csengery A, Schmenk J, Frederick K. Development of CYP11B1 and CYP11B2 assays utilizing homogenates of adrenal glands: utility of monkey as a surrogate for human. J Steroid Biochem Mol Biol. 2015;154:197–205. doi:10.1016/j.jsbmb.2015.08.004.PubMedCrossRef

95.

Armani A, Cinti F, Marzolla V, Morgan J, Cranston GA, Antelmi A, et al. Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice. FASEB J. 2014;28(8):3745–57. doi:10.1096/fj.13-245415.PubMedCrossRef

96.••

Garg R, Kneen L, Williams GH, Adler GK. Effect of mineralocorticoid receptor antagonist on insulin resistance and endothelial function in obese subjects. Diabetes Obes Metab. 2014;16(3):268–72. doi:10.1111/dom.12224. This paper reports the results of the single clinical study of MR antagonists for the treatment of obesity, However only non-diabetic healthy obese were included in the study.PubMedPubMedCentralCrossRef

97.

Peelman F, Zabeau L, Moharana K, Savvides SN, Tavernier J. 20 years of leptin: insights into signaling assemblies of the leptin receptor. J Endocrinol. 2014;223(1):T9–23. doi:10.1530/joe-14-0264.PubMedCrossRef

98.

Gertler A, Solomon G. Leptin-activity blockers: development and potential use in experimental biology and medicine. Can J Physiol Pharmacol. 2013;91(11):873–82. doi:10.1139/cjpp-2013-0012.PubMedCrossRef

99.

Okada-Iwabu M, Iwabu M, Ueki K, Yamauchi T, Kadowaki T. Perspective of small-molecule adipoR agonist for type 2 diabetes and short life in obesity. Diabetes Metab J. 2015;39(5):363–72. doi:10.4093/dmj.2015.39.5.363.PubMedPubMedCentralCrossRef

100.

Lim S, Quon MJ, Koh KK. Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis. 2014;233(2):721–8. doi:10.1016/j.atherosclerosis.2014.01.051.PubMedCrossRef

101.•

Tanabe H, Fujii Y, Okada-Iwabu M, Iwabu M, Nakamura Y, Hosaka T, et al. Crystal structures of the human adiponectin receptors. Nature. 2015;520(7547):312–6. doi:10.1038/nature14301. This paper reports the crystal structures of human AdipoR1 and AdipoR2, a novel class of receptor structures, with a seven-transmembrane helices arrangement, conformationally distinct from those of G-protein-coupled receptors.PubMedPubMedCentralCrossRef

Titel: Aldosterone Production and Signaling Dysregulation in Obesity
verfasst von: Andrea Vecchiola
Carlos F. Lagos
Cristian A. Carvajal
Rene Baudrand
Carlos E. Fardella
Publikationsdatum: 01.03.2016
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 3/2016
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-016-0626-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2016

Major Autonomic Neuroregulatory Pathways Underlying Short- and Long-Term Control of Cardiovascular Function

Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?

Parasympathetic Vagal Control of Cardiac Function

Role of Inflammation and Immunity in Hypertension: Recent Epidemiological, Laboratory, and Clinical Evidence

Personalized Therapy of Hypertension: the Past and the Future